Friday, Jul 24, 2026 The claims desk. Receipts included. POWERED BY LENZ ↗
IsThis

HEALTH

The Claim

Scientific studies report an association between CYP2C19 genetic variants and major depressive disorder, longer depressive episodes, and greater depressive symptom severity.

Verified by Lenz ·

The Short Version

Published studies do report these associations. Systematic reviews and several primary studies describe links between CYP2C19 variants and depression risk, longer episodes, or greater symptom severity, even though results are mixed overall. The claim stays within what the evidence supports because it says studies report an association, not that the association is proven or universal.

Caveats

  • The literature is mixed: several studies found no association, so this should not be read as settled consensus.
  • CYP2C19 is better established in antidepressant metabolism than as a confirmed direct risk gene for depression itself.
  • Findings may vary by ancestry, specific variant, phenotype definition, and study design, which limits generalization.

The Receipts

  1. CYP2C19 Genetic Variants and Major Depressive Disorder

    PubMed Central

  2. Effectiveness of pharmacogenomic tests including CYP2D6 and CYP2C19 genomic variants for guiding the treatment of depressive disorders: Systematic review and meta-analysis of randomised controlled trials

    PubMed

  3. Effectiveness of pharmacogenomic tests including CYP2D6 and CYP2C19 genomic variants for guiding the treatment of depressive disorders: Systematic review and meta-analysis of randomised controlled trials

    ScienceDirect

  4. Influence of combined CYP2C19 and CYP2D6 phenotypes on antidepressant-related adverse drug reactions in patients with depression

    Nature

  5. The impact of CYP2C19 genotypes on steady-state plasma concentrations of escitalopram and its primary metabolite desmethylescitalopram

    Pharmacia

  6. CYP2C19 gene

    MedlinePlus Genetics (NIH)

  7. CYP2C19 Genetic Variants and Major Depressive Disorder: A Systematic Review

    PubMed

  8. Effect of CYP2C19 polymorphisms on antidepressant prescription patterns and treatment outcomes in patients with major depressive disorder and bipolar disorder

    Neuropsychopharmacology Reports (Nature)

  9. Effects of CYP2C19 genetic polymorphism on the steady-state concentration of citalopram in patients with major depressive disorder

    PubMed

  10. Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment

    Nature

+ 22 more sources — see the full list on Lenz

Filed Under

CYP2C19Major Depressive Disorder

More Fact Checks